Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2005-07-20
2010-06-01
Harris, Alana M (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S138100, C436S057000, C436S064000, C436S164000, C514S001000, C514S002600
Reexamination Certificate
active
07727528
ABSTRACT:
Labeled antibodies, antibody fragments or peptides binding to soluble cytokines or cytokine receptors are used to diagnose whether a patient has cancer or an autoimmune disease. In a preferred embodiment, a radiolabelled tag that is chemically bound to a peptide, antibody, or antibody fragment specific for sTNFR-1 and/or sTNFR2 is injected into a patient with a tumor, or suspected tumor, or with any disease associated with STNF-1/STNF-2. The patient is then imaged using standard nuclear imaging equipment to detect areas or sites of concentration of the radiolabel and/or receptor/inhibitor and/or antigen. By screening for cancer by the substances it produces, using an injected antibody to that substance with a tracer attached to it, one can detect cancer at a very early stage, potentially even microscopically.
REFERENCES:
patent: 2002/0012665 (2002-01-01), Hanna
patent: 2002/0146369 (2002-10-01), Goldenberg
patent: 2003/0054421 (2003-03-01), Rosen et al.
patent: 2003/0138426 (2003-07-01), Ni et al.
patent: 2003/0185832 (2003-10-01), Thorpe et al.
patent: 2005/0089928 (2005-04-01), Short et al.
patent: WO 94/02627 (1994-02-01), None
patent: WO 03/056896 (2003-07-01), None
patent: WO 2005/107802 (2005-11-01), None
Lavabre-Bertrand, Thierry. Detection of membrane and soluble interleukin-6 receptor in lymphoid malignancies British Journal of Haematology 91(4): 871-877, Dec. 1995.
Qui, Yuhua et al. Establishment and application of radioimmunoassay for detecting human soluble IL-6Ralpha. Zhonghua Jianyan Yixue Zazhi 26(7): 424-427, 2003.
Abbate, et al., “Tumor necrosis factor and soluble interleukin-2 receptor: two immunological biomarkers in female neoplasms”,Eur J Gynaecol Oncol, 13(1 Suppl):92-6 (1992).
Adair, “Engineering antibodies for therapy”,Immunol. Rev., 130:5-40 (1992).
Aggarwal, et al., “The role of TNF and its family members in inflammation and cancer: lessons from gene deletion”,Curr Drug Targets Inflamm Allergy, 1(4):327-41 (2002).
Ardizzoia, et al., “Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease”,J Biol Regul Homeost Agents, 6(3):103-7 (1992).
Berkower, “The promise and pitfalls of monoclonal antibody therapeutics”,Curr. Opin. Biotechnology, 7:622-8 (1996).
Bjornberg, et al., “Mechanisms involved in the processing of the p55 and the p75 tumor necrosis factor (TNF) receptors to soluble receptor forms”,Lymphokine Cytokine Res., 13(3):203-11 (1994).
Bouwmeester, et al., “A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway”,Nat Cell Biol, 6(2):97-105 (2004).
Brumley, et al., “Radiolabeled monoclonal antibodies”,AORN J., 62: 343-355 (1995).
Clackson, et al., “Making antibody fragments using phage display libraries”,Nature, 352(6336):624-688 (1991).
Csehi, et al., “Tumor necrosis factor (TNF) interferes with insulin signaling through the p55 TNF receptor death domain”,Biochem Biophys Res Commun, 329(1):397-405 (2005).
Daugherty, et al.,Nucl. Acids Res., “Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins”, 19:2471-2476 (1991).
Eliopoulos, et al., “The role of the CD40 pathway in the pathogenesis and treatment of cancer”Curr Opin Pharmacol, 4(4):360-7 (2004).
Engelmann, et al., “Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors”,J Biol Chem, 265(3):1531-6 (1990).
Feng, “Regulatory roles and molecular signaling of TNF family members in osteoclasts”,Gene, 350(1):1-13 (2005).
Forrest, et al., “Modulation of cytokine release by purine receptors in patients with rheumatoid arthritis,”Clin Exp Rheumatol., 23(1):89-92 (2005).
Fraker, et al., “Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril”,Biochem. Biophys. Res. Commun., 80:849-857 (1978).
Gadducci, et al., “Serum levels of soluble receptors for tumor necrosis factor (p55 and p75 sTNFr) in endometrial cancer”,Anticancer Res, 16(5B):3125-8 (1996).
Gadducci, et al., “Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer”,Gynecol Oncol, 58(2):184-8 (1995).
Golovko, et al., “Vitamin D-induced up-regulation of tumour necrosis factor alpha (TNF-alpha) in prostate cancer cells”,Life Sci., 77(5):562-77 (2005).
Grell, et al., “The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor”,Proc Natl Acad Sci U S A., 95(2):570-5 (1998).
Grosen, et al., “Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy”,Gynecol Oncol, 50(1):68-77 (1993).
Hadziselimovic, “Reply: Urinary excretion of TNF receptors”,Gut, 38(1):153-4 (1996), Abstract only.
Hasegawa, et al, “Increased soluble tumor necrosis factor receptor levels in the serum of elderly people”,Gerontology, 46(4):185-8 (2000).
Holtmann, et al., “The emerging distinct role of TNF-receptor 2 (p80) signaling in chronic inflammatory disorders”,Arch Immunol Ther Exp(Warsz), 50(4):279-88 (2002).
Hyer, et al., “Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells”,Cancer Res, 65(11):4799-808 (2005).
Iborra, et al., “Oxidative stress and autoimmune response in the infertile woman”,Chem Immunol Allergy, 88:150-62 (2005).
Ireland, et al., “Interleukin (IL)-12 receptor beta1 or IL-12 receptor beta 2 deficiency in mice indicates that IL-12 and IL-23 are not essential for host recovery from viral encephalitis”,Viral Immunol., 18(2):397-402 (2005).
Jaakkola, “In vivo detection of vascular adhesion protein-1 in experimental inflammation”,Amer.J. Pathol., 157:463-471 (2000).
Jablonska, et al., “Tumor necrosis factor-alpha and soluble tumor necrosis factor receptors in the culture supernatants of polymorphonuclear cells and peripheral blood mononuclear cells from cancer patients”,Eur Cytokine Netw, 9(2):155-9 (1998).
Jacob, et al., “Fiber-modified adenoviral vector expressing the tumor necrosis factor-related apoptosis-inducing ligand gene from the human telomerase reverse transcriptase promoter induces apoptosis in human hepatocellular carcinoma cells”,World J Gastroenterol, 11(17):2552-6 (2005).
Jakobovits, “The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice”,Exp. Opin. Invest. Drugs, 7:607-614 (1998).
Kim, et al., “Identification of naturally secreted soluble form of TL1A, a TNF-like cytokine”,J Immunol Methods, 298(1-2):1-8 (2005).
Lentz, “The phylogeny of oncology,”Mol Biotherm., 2:137-144 (1990).
Liu, et al., “Molecular mechanism of TNF signaling and beyond”,Cell Res, 15(1):24-7 (2005).
Macallan, et al., “Development of a novel TNF alpha ligand-receptor binding assay for screening NATCHEM Libraries”,J Recept Signal Transduct Res, 17(1-3):521-9 (1997).
Maier, et al., “Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: a normative study”,J Neurotrauma, 22(7):822-35 (2005).
Malmberg, “Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?”Cancer Immunol Immunother, 53(10):879-92 (2004).
Mendez, et al., “Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice”,Nat. Genet., 15:146-156 (1997).
Mercer, et al., “Natural
Early Detection, LLC
Harris Alana M
Pabst Patent Group LLP
LandOfFree
Methods for diagnosis using anti-cytokine receptor antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for diagnosis using anti-cytokine receptor antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for diagnosis using anti-cytokine receptor antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4245894